Effects of Androgen Ablation on Anti-Tumor Immunity
Abstract
Androgen ablation constitutes the most common therapy for the treatment of advanced prostate cancer. While initially effective at reducing tumor burden, most patients recur with androgen insensitive disease. There exists a clear need to augment the clinical efficacy of hormone-based therapies and immunotherapy of prostate cancer represents one such promising approach. The induction of apoptotic cell death in the prostate is accompanied by an inflammatory infiltrate comprised predominantly of activated T cells. This AA induced autoimmune-like response exerts limited anti-tumor activity in a murine prostate cancer model, but could be synergistic with CTLA-4 blockade that promotes the development of autoreactive T cell. In the past year, we have established stable clonal cell lines expressing the CD80 molecule that increases the immunogenicity of the tumor cells, set up the tumor models and performed dose-titration experiments and examined the effects of castration on existing tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2004
- Accession Number
- ADA430317
Entities
People
- Martin Kast
Organizations
- Loyola University New Orleans